Lifestyle program to help keep the uterus in early cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether a lifestyle transformation can help treat complex atypical endometrial hyperplasia or early (grade 1) endometrial cancer without removing the uterus. It may help support uterine preservation for people who want to keep fertility or avoid hysterectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with complex atypical endometrial hyperplasia or grade 1 endometrial cancer, confirmed by tissue testing (biopsy).
- You are premenopausal (still having periods) and still have your uterus.
- You are age 18 to 45, and your general health is good enough for daily activities (ECOG 0–2).
- Your body mass index (BMI) is 30 or higher (in the obese range), and you are willing to get an LNG-IUD placed at the start of the study.
- You are not currently using chemotherapy or radiation for any cancer, and you do not have an active pelvic infection or another reason you can’t safely use an IUD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether certain treatments can help women aged 18-45 with early-stage endometrial cancer or precancerous changes keep their ability to have children. It uses imaging scans to make sure the cancer hasn't spread.
This trial studies whether removing an early, hormone-responsive uterine growth using a procedure through the cervix can keep fertility possible. It is for people under 40 with a specific low-risk uterine biopsy and MRI findings who have already tried hormone treatment.
This study looks at women with endometrial adenocarcinoma or atypical hyperplasia who had conservative treatment instead of radical surgery. It aims to check how well the treatment works for both cancer and future pregnancy outcomes.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
Hear when a new Endometrial Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.